Appraisal of donor steatosis in liver transplantation: a survey of current practice in Australia and New Zealand

IF 0.1 Q4 TRANSPLANTATION
A. Dare, A. Phillips, M. Chu, A. Hickey, A. Bartlett
{"title":"Appraisal of donor steatosis in liver transplantation: a survey of current practice in Australia and New Zealand","authors":"A. Dare, A. Phillips, M. Chu, A. Hickey, A. Bartlett","doi":"10.2147/TRRM.S33407","DOIUrl":null,"url":null,"abstract":"Correspondence: Adam Bartlett New Zealand Liver Transplant Unit, Level 15, Support Building, Auckland City Hospital, 2 Park Road, Grafton, Auckland 1023, New Zealand Tel +64 21 241 4647 Fax +64 9 375 4345 Email a.bartlett@auckland.ac.nz Background: Hepatic steatosis is increasingly encountered among organ donors. Currently, there is no consensus guideline as to the type or degree of donor steatosis considered acceptable for liver transplantation (LT), and little is known about local practices in this area. The aim of this survey was to evaluate current clinical practices amongst liver transplant surgeons in Australia and New Zealand (ANZ) in the evaluation and use of steatotic donor livers in LT. Methods: An anonymous online twelve-question survey was emailed to all practicing LT surgeons in ANZ (n = 23) in January 2010. Results: The response rate was 83%. Estimated prevalence of steatosis in donor livers was between 40% and 60%. In determining suitability for LT, 90% of respondents reported rejecting organs with “severe” steatosis based on visual and palpation grounds alone. A total of 68% sought further histological assessment if the donor liver looked bad and there were risk factors for steatosis. The majority of respondents performed only one biopsy of the liver (79%), using hematoxylin and eosin staining for fat assessment (53%). There was wide variation in the upper limit of steatosis considered to be acceptable for LT (40%–80% steatosis). A total of 21% of respondents still considered microvesicular steatosis a risk factor for primary graft nonfunction. Conclusion: This survey highlights the significant variation in the appraisal and use of steatotic grafts by LT surgeons in ANZ. Accurate evaluation and judicious use of mild and moderately steatotic grafts is required if we are to utilize the available donor pool best.","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"4 1","pages":"31-37"},"PeriodicalIF":0.1000,"publicationDate":"2012-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S33407","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplant Research and Risk Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/TRRM.S33407","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"TRANSPLANTATION","Score":null,"Total":0}
引用次数: 7

Abstract

Correspondence: Adam Bartlett New Zealand Liver Transplant Unit, Level 15, Support Building, Auckland City Hospital, 2 Park Road, Grafton, Auckland 1023, New Zealand Tel +64 21 241 4647 Fax +64 9 375 4345 Email a.bartlett@auckland.ac.nz Background: Hepatic steatosis is increasingly encountered among organ donors. Currently, there is no consensus guideline as to the type or degree of donor steatosis considered acceptable for liver transplantation (LT), and little is known about local practices in this area. The aim of this survey was to evaluate current clinical practices amongst liver transplant surgeons in Australia and New Zealand (ANZ) in the evaluation and use of steatotic donor livers in LT. Methods: An anonymous online twelve-question survey was emailed to all practicing LT surgeons in ANZ (n = 23) in January 2010. Results: The response rate was 83%. Estimated prevalence of steatosis in donor livers was between 40% and 60%. In determining suitability for LT, 90% of respondents reported rejecting organs with “severe” steatosis based on visual and palpation grounds alone. A total of 68% sought further histological assessment if the donor liver looked bad and there were risk factors for steatosis. The majority of respondents performed only one biopsy of the liver (79%), using hematoxylin and eosin staining for fat assessment (53%). There was wide variation in the upper limit of steatosis considered to be acceptable for LT (40%–80% steatosis). A total of 21% of respondents still considered microvesicular steatosis a risk factor for primary graft nonfunction. Conclusion: This survey highlights the significant variation in the appraisal and use of steatotic grafts by LT surgeons in ANZ. Accurate evaluation and judicious use of mild and moderately steatotic grafts is required if we are to utilize the available donor pool best.
肝移植中供体脂肪变性的评价:澳大利亚和新西兰当前实践的调查
通讯:Adam Bartlett新西兰肝移植科,奥克兰格拉夫顿公园路2号奥克兰市医院支持楼15层,新西兰奥克兰1023电话+64 21 241 4647传真+64 9 375 4345电子邮件a.bartlett@auckland.ac.nz背景:肝脏脂肪变性越来越多地出现在器官捐赠者中。目前,对于肝移植(LT)可接受的供体脂肪变性的类型或程度,没有一致的指导方针,而且对该地区的当地实践知之甚少。本调查的目的是评估目前澳大利亚和新西兰(ANZ)肝移植外科医生在肝移植中评估和使用脂肪变性供肝的临床实践。方法:2010年1月,通过电子邮件向ANZ所有执业肝移植外科医生(n = 23)发送了一份包含12个问题的匿名在线调查。结果:有效率为83%。估计供体肝脏脂肪变性的患病率在40%到60%之间。在确定肝移植的适宜性时,90%的应答者报告仅根据视觉和触诊理由排斥“严重”脂肪变性的器官。如果供体肝脏看起来很差并且存在脂肪变性的危险因素,总共68%的患者寻求进一步的组织学评估。大多数应答者只进行一次肝脏活检(79%),使用苏木精和伊红染色进行脂肪评估(53%)。肝移植可接受的脂肪变性上限(40%-80%脂肪变性)差异很大。总共21%的应答者仍然认为微囊性脂肪变性是原发性移植物功能不全的危险因素。结论:这项调查强调了澳新银行LT外科医生在评估和使用脂肪变性移植物方面的显著差异。如果我们要最好地利用现有的供体库,就需要准确评估和明智地使用轻度和中度脂肪变性移植物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.70
自引率
0.00%
发文量
6
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信